Qilu Pharmaceutical is paying 280 million Chinese yuan ($38 million) for a licensing and collaboration deal with fellow China ...

During a live event, Krish Patel, MD, surveyed participants on using bispecific T-cell engagers vs loncastuximab in a patient ...

Formosa Pharmaceuticals Inc. and Almac Discovery Ltd. have announced a global licensing agreement for development and commercialization of ALM-401, a first-in-class engineered bispecific antibody-drug ...

Veraxa Biotech has entered a joint discovery partnership with OmniAb tp develop a bispecific antibody drug conjugate (bsADC) ...

The idea is that the longer you wait, you should be going back to the step-up dosing. But you don't see the recurrent CRS signal. If you look at the label, the label has all of these recommendations.

SAN FRANCISCO and SUZHOU, China, April 27, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that ...

Comprehensive preclinical results will be presented for Debio 1562M, a next-generation Antibody-Drug Conjugate (ADC) targeting the cell surface glycoprotein CD37 soon to undergo first-in-human ...

Superb internalization profile paired with proprietary linker technology underscore strong efficacy and optimal stability data; first-in-class ADC program currently in IND-enabling studies ...

Session Title: Antibody-Based Cancer Therapeutics 2 ZW327 is a potential first-in-class ADC targeting Ly6E ... a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric ...

Keymed's ADC platform: a next-generation of proprietary ADC program for innovative drug development Keymed's proprietary ADC platform has capabilities for developing next-generation ADCs with novel ...